{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:47:15Z","timestamp":1789224435618,"version":"build-2803163510"},"reference-count":77,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2023,9,2]]},"DOI":"10.1080\/14712598.2023.2248878","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T06:16:37Z","timestamp":1692598597000},"page":"869-876","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma"],"prefix":"10.1080","volume":"23","author":[{"given":"Aditi","family":"Saha","sequence":"first","affiliation":[{"name":"Department of Medicine\/Hematology Oncology, University of South Florida, Tampa, FLUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushali","family":"Jhaveri","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Hematology Oncology, University of South Florida, Tampa, FLUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humaira","family":"Sarfraz","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Hematology Oncology, University of South Florida, Tampa, FLUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2045-6238","authenticated-orcid":false,"given":"Julio C","family":"Chavez","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,8,20]]},"reference":[{"issue":"7","key":"e_1_3_5_3_1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio R","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022 Jul 01;36(7):1720\u20131748.","journal-title":"Leukemia"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"issue":"3","key":"e_1_3_5_5_1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/annonc\/mds517","article-title":"ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)","volume":"24","author":"Ghielmini M","year":"2013","unstructured":"Ghielmini M, Vitolo U, Kimby E, et al. ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2013 Mar 01;24(3):561\u2013576.","journal-title":"Ann Oncol"},{"issue":"1","key":"e_1_3_5_6_1","doi-asserted-by":"crossref","first-page":"14610","DOI":"10.1038\/s41598-020-71579-6","article-title":"Population-based epidemiological data of follicular lymphoma in Poland: 15 years of observation","volume":"10","author":"Szumera-Cie\u0107kiewicz A","year":"2020","unstructured":"Szumera-Cie\u0107kiewicz A, Wojciechowska U, Didkowska J, et al. Population-based epidemiological data of follicular lymphoma in Poland: 15 years of observation. Sci Rep. 2020 Sep 03;10(1):14610.","journal-title":"Sci Rep"},{"key":"e_1_3_5_7_1","unstructured":"Surveillance epidemiology and end results program. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/follicular.html"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25696"},{"issue":"1","key":"e_1_3_5_9_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone A","year":"2019","unstructured":"Carbone A, Roulland S, Gloghini A, et al. Follicular lymphoma. Nat Rev Dis Primers. 2019 Dec 12;5(1):83.","journal-title":"Nat Rev Dis Primers"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.175"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.0283"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30090-5"},{"issue":"5","key":"e_1_3_5_13_1","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny P","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004 Sep 1;104(5):1258\u20131265.","journal-title":"Blood"},{"issue":"27","key":"e_1_3_5_14_1","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico M","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009 Sep 20;27(27):4555\u20134562.","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00169-2"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.251"},{"issue":"23","key":"e_1_3_5_18_1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare study","volume":"33","author":"Casulo C","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare study. J Clin Oncol. 2015 Aug 10;33(23):2516\u20132522.","journal-title":"J Clin Oncol"},{"issue":"7","key":"e_1_3_5_19_1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare study (NLCS)","volume":"126","author":"Wagner-Johnston ND","year":"2015","unstructured":"Wagner-Johnston ND, Link BK, Byrtek M, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare study (NLCS). Blood. 2015 Aug 13;126(7):851\u2013857.","journal-title":"Blood"},{"issue":"3","key":"e_1_3_5_20_1","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","article-title":"Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy","volume":"64","author":"Guadagnolo BA","year":"2006","unstructured":"Guadagnolo BA, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):928\u2013934.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"29","key":"e_1_3_5_21_1","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","article-title":"Randomized trial of systemic therapy after involved-field radiotherapy in patients with Early-stage follicular lymphoma: TROG 99.03","volume":"36","author":"MacManus M","year":"2018","unstructured":"MacManus M, Fisher R, Roos D, et al. Randomized trial of systemic therapy after involved-field radiotherapy in patients with Early-stage follicular lymphoma: TROG 99.03. J Clin Oncol. 2018 Oct 10;36(29):2918\u20132925.","journal-title":"J Clin Oncol"},{"issue":"8","key":"e_1_3_5_22_1","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","article-title":"Stage I and II follicular non-Hodgkin\u2019s lymphoma: long-term follow-up of no initial therapy","volume":"22","author":"Advani R","year":"2004","unstructured":"Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin\u2019s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004 Apr 15;22(8):1454\u20131459.","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"issue":"14","key":"e_1_3_5_26_1","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus R","year":"2017","unstructured":"Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331\u20131344.","journal-title":"N Engl J Med"},{"issue":"9873","key":"e_1_3_5_27_1","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel MJ","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Apr 6;381(9873):1203\u20131210.","journal-title":"Lancet"},{"issue":"12","key":"e_1_3_5_28_1","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn IW","year":"2019","unstructured":"Flinn IW, van der Jagt R, Kahl B, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019 Apr 20;37(12):984\u2013991.","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx496"},{"issue":"10","key":"e_1_3_5_31_1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced Untreated follicular lymphoma","volume":"379","author":"Morschhauser F","year":"2018","unstructured":"Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus lenalidomide in advanced Untreated follicular lymphoma. N Engl J Med. 2018 Sep 6;379(10):934\u2013947.","journal-title":"N Engl J Med"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-717355"},{"issue":"27","key":"e_1_3_5_33_1","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma","volume":"26","author":"Robinson KS","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008 Sep 20;26(27):4473\u20134479.","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.12.771"},{"issue":"10","key":"e_1_3_5_35_1","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers MH","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006 Nov 15;108(10):3295\u20133301.","journal-title":"Blood"},{"issue":"14","key":"e_1_3_5_36_1","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard JP","year":"2019","unstructured":"Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019 May 10;37(14):1188\u20131199.","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30097-3"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00033-3"},{"issue":"11","key":"e_1_3_5_39_1","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal AK","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014 Mar 13;370(11):1008\u20131018.","journal-title":"N Engl J Med"},{"issue":"11","key":"e_1_3_5_40_1","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of Duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Flinn IW","year":"2019","unstructured":"Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: a phase II study of Duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019 Apr 10;37(11):912\u2013922.","journal-title":"J Clin Oncol"},{"issue":"35","key":"e_1_3_5_41_1","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling M","year":"2017","unstructured":"Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017 Dec 10;35(35):3898\u20133905.","journal-title":"J Clin Oncol"},{"issue":"15","key":"e_1_3_5_42_1","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3Kdelta\/CK1epsilon inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler NH","year":"2021","unstructured":"Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib, a dual PI3Kdelta\/CK1epsilon inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol. 2021 May 20;39(15):1609\u20131618.","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30441-1"},{"issue":"26","key":"e_1_3_5_44_1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu SS","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531\u20132544.","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_3_5_45_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma","volume":"380","author":"Schuster SJ","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019 Jan 3;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"10254","key":"e_1_3_5_46_1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson JS","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020 Sep 19;396(10254):839\u2013852.","journal-title":"Lancet"},{"issue":"7","key":"e_1_3_5_47_1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma","volume":"386","author":"Locke FL","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma. N Engl J Med. 2022 Feb 17;386(7):640\u2013654.","journal-title":"N Engl J Med"},{"issue":"10343","key":"e_1_3_5_48_1","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar M","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022 Jun 18;399(10343):2294\u20132308.","journal-title":"Lancet"},{"issue":"1","key":"e_1_3_5_49_1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang K","year":"2012","unstructured":"Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012 Nov 29;1(1):36.","journal-title":"Exp Hematol Oncol"},{"issue":"20","key":"e_1_3_5_50_1","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer JN","year":"2010","unstructured":"Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010 Nov 18;116(20):4099\u20134102.","journal-title":"Blood"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01467"},{"issue":"7","key":"e_1_3_5_52_1","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","author":"Hirayama AV","year":"2019","unstructured":"Hirayama AV, Gauthier J, Hay KA, et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood. 2019 Aug 15;134(7):636\u2013640.","journal-title":"Blood"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-156120"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138983"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719841581"},{"issue":"2","key":"e_1_3_5_57_1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar Z","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720\u2013724.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"e_1_3_5_58_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang C","year":"2017","unstructured":"Zhang C, Liu J, Zhong JF, et al. Engineering CAR-T cells. Biomark Res. 2017 Jun 24;5(1):22.","journal-title":"Biomark Res"},{"issue":"7","key":"e_1_3_5_59_1","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1517\/14712598.2011.573476","article-title":"Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy","volume":"11","author":"Ramos CA","year":"2011","unstructured":"Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. 2011 Jul 01;11(7):855\u2013873.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"e_1_3_5_60_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jocit.2016.08.001","article-title":"Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: summary and perspective","volume":"2","author":"Smith AJ","year":"2016","unstructured":"Smith AJ, Oertle J, Warren D, et al. Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: summary and perspective. J Cell Immunother. 2016 Nov 01;2(2):59\u201368.","journal-title":"J Cell Immunother"},{"issue":"1","key":"e_1_3_5_61_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew N","year":"2019","unstructured":"Tokarew N, Ogonek J, Endres S, et al. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019 Jan 01;120(1):26\u201337.","journal-title":"Br J Cancer"},{"issue":"5","key":"e_1_3_5_62_1","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes","volume":"181","author":"Brocker T","year":"1995","unstructured":"Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med. 1995 May 1;181(5):1653\u20131659.","journal-title":"J Exp Med"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4597"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46110"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S138765"},{"issue":"1","key":"e_1_3_5_66_1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbcan.2015.12.001","article-title":"Clinical pharmacology of CAR-T cells: linking cellular pharmacodynamics to pharmacokinetics and antitumor effects","volume":"1865","author":"Norelli M","year":"2016","unstructured":"Norelli M, Casucci M, Bonini C, et al. Clinical pharmacology of CAR-T cells: linking cellular pharmacodynamics to pharmacokinetics and antitumor effects. Biochimica Et Biophysica Acta (BBA) - Reviews On Cancer. 2016 Jan 01;1865(1):90\u2013100.","journal-title":"Biochimica Et Biophysica Acta (BBA) - Reviews On Cancer"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2030164"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158024"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157691"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158404"},{"issue":"18","key":"e_1_3_5_78_1","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-Cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-Cell lymphoma: a phase I trial","volume":"39","author":"Hutchings M","year":"2021","unstructured":"Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-Cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-Cell lymphoma: a phase I trial. J Clin Oncol. 2021 Jun 20;39(18):1959\u20131970.","journal-title":"J Clin Oncol"},{"issue":"10306","key":"e_1_3_5_79_1","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings M","year":"2021","unstructured":"Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study. Lancet. 2021 Sep 25;398(10306):1157\u20131169.","journal-title":"Lancet"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2023.2248878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T10:36:49Z","timestamp":1695638209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2023.2248878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,20]]},"references-count":77,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,2]]}},"alternative-id":["10.1080\/14712598.2023.2248878"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2023.2248878","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}